Emilia Bulaevsky Zychlinsky
Chief Operating Officer chez Exai Bio, Inc.
Profil
Emilia Bulaevsky Zychlinsky is currently the Executive Vice President-Operations at Exai Bio, Inc. She previously worked as the Senior VP-Regulatory Affairs & Quality Assurance at Standard BioTools, Inc. and as the Vice President-Operations, Research & Development at Minaris Medical America, Inc. From 2011 to 2016, she was the Chief Technical Officer & Executive Vice President at Diadexus, Inc. Dr. Zychlinsky holds a doctorate degree from Stanford University and an undergraduate degree from Instituto Politecnico Nacional.
Postes actifs de Emilia Bulaevsky Zychlinsky
Sociétés | Poste | Début |
---|---|---|
Exai Bio, Inc.
Exai Bio, Inc. Packaged SoftwareTechnology Services Exai Bio, Inc. is an American next-generation liquid biopsy company founded by Hani Goodarzi, Babak Alipanahi, and Patrick Arensdorf. The company's mission is to enable early detection, accurate diagnosis, personalized and targeted treatment, and ultimately cure of cancer. Exai Bio's proprietary RNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest and most accurate diagnosis of cancer. Patrick Arensdorf has been the CEO since incorporation. | Chief Operating Officer | 02/02/2023 |
Anciens postes connus de Emilia Bulaevsky Zychlinsky
Sociétés | Poste | Fin |
---|---|---|
DIADEXUS, INC. | Chief Tech/Sci/R&D Officer | 01/04/2016 |
Minaris Medical America, Inc.
Minaris Medical America, Inc. Medical SpecialtiesHealth Technology Minaris Medical America, Inc. manufactures the CLA and OPTIGEN Allergy Tests, in vitro diagnostic tests and alternative to skin tests. It serves the medical community through its Allos Reference Laboratory. The firm’s products include the CLA Allergen-Specific IgE Assay, theOPTIGEN Allergen-Specific IgE Assay, CLA-1 Luminometer In Vitro Allergy Diagnostic System and AP 720S Semi-Automated In Vitro Allergy Diagnostic System. The company is headquartered in Mountain View, CA. | Chief Tech/Sci/R&D Officer | - |
STANDARD BIOTOOLS INC. | General Counsel | - |
Formation de Emilia Bulaevsky Zychlinsky
Stanford University | Doctorate Degree |
Instituto Politecnico Nacional | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
STANDARD BIOTOOLS INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Minaris Medical America, Inc.
Minaris Medical America, Inc. Medical SpecialtiesHealth Technology Minaris Medical America, Inc. manufactures the CLA and OPTIGEN Allergy Tests, in vitro diagnostic tests and alternative to skin tests. It serves the medical community through its Allos Reference Laboratory. The firm’s products include the CLA Allergen-Specific IgE Assay, theOPTIGEN Allergen-Specific IgE Assay, CLA-1 Luminometer In Vitro Allergy Diagnostic System and AP 720S Semi-Automated In Vitro Allergy Diagnostic System. The company is headquartered in Mountain View, CA. | Health Technology |
Diadexus, Inc.
Diadexus, Inc. BiotechnologyHealth Technology Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
Exai Bio, Inc.
Exai Bio, Inc. Packaged SoftwareTechnology Services Exai Bio, Inc. is an American next-generation liquid biopsy company founded by Hani Goodarzi, Babak Alipanahi, and Patrick Arensdorf. The company's mission is to enable early detection, accurate diagnosis, personalized and targeted treatment, and ultimately cure of cancer. Exai Bio's proprietary RNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest and most accurate diagnosis of cancer. Patrick Arensdorf has been the CEO since incorporation. | Technology Services |